The drug and biotech sector has shown signs of recovery since mid-2025, driven by strong quarterly results, rising mergers and acquisitions, and regulatory successes. Numerous companies in this space are focusing on high-interest areas like obesity treatments and gene therapy despite facing challenges such as patent expirations and regulatory uncertainties. The Zacks Medical-Drugs industry now ranks #90 among 243 industries, reflecting a promising growth outlook.
Key players benefiting from the recovery include Catalyst Pharmaceuticals, Indivior Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics. For instance, Indivior’s Sublocade treatment for opioid use disorder generated $856 million in net revenues in 2025, while Catalyst’s Firdapse for Lambert-Eaton Myasthenic Syndrome has secured patent protections until 2035. Collectively, these companies have experienced notable stock performance; for example, Relmada’s stock has surged by 206% in the past six months.
As of 2026, the Zacks Medical-Drugs industry trades at a trailing price-to-sales ratio of 2.55, indicating potential undervaluation compared to the S&P 500’s ratio of 5.50. Continued investment in innovative technologies and strong M&A activity are expected to fuel this sector’s growth amid a changing global healthcare landscape.
